OS and PFS. (A) Shows OS among all the patients. The median OS was not reached, and the estimated OS probability at 48 months was 84% (90% CI, 63-93%). (B) Shows the OS of patients on first-line ibrutinib compared with those enrolled in the study with relapsed or refractory disease (P = .35, log-rank test). (C) Shows PFS among all the patients. Median PFS was not reached, and the estimated PFS at 48 months was 80% (90% CI, 46-85%). (D) Shows the PFS of patients receiving first-line ibrutinib compared with those enrolled in the study with relapsed or refractory disease (P = .15, log-rank test). Tick marks indicate censored data.